Skip to main content
. 2019 Jun 3;18(13):1513–1522. doi: 10.1080/15384101.2019.1624113

Figure 2.

Figure 2.

HER2-L755S is highly resistant to both reversible and irreversible TKIs. (a and b) The dose response of indicated MCF10A cells to lapatinib treatment in monolayer for 4 days (a) and in soft-agar for 14 days (b). (c and d). The dose response of indicated MCF10A cells to neratinib treatment in monolayer for 4 days (c) and in soft-agar for 14 days (d). Data are expressed as means ± SEM. of three technical replicates.